未登录AI-driven spatial mapping of myxoid stroma and tumor-infiltrating lymphocytes in esophageal squamous cell carcinomaAI驱动的粘液性基质和肿瘤浸润淋巴细胞在食管鳞状细胞癌中的空间映射
Kouzu, Keita; Tsujimoto, Hironori; Nearchou, Ines P.; Einama, Takahiro; Kajiwara, Yoshiki; Watanabe, Takanori; Koga, Makiko; Tsuru, Tomohiro; Horiguchi, Hiroyuki; Yaguchi, Yoshihisa; Kishi, Yoji; Tsuda, Hitoshi; Ueno, Hideki .png)
分享.png)
收藏ASO Visual Abstract: Clinical Significance of Coiled-Coil Domain-Containing Protein 25 Expression in Esophageal Squamous Cell CancerSuzuki, Takafumi; Tsujimoto, Hironori; Watanabe, Takanori; Ishibashi, Yusuke; Fujishima, Seiichiro; Itazaki, Yujiro; Kariya, Risa; Uehata, Naoyuki; Shinada, Hanae; Mochizuki, Satsuki; Kishi, Yoji; Sato, Kimiya; Ueno, Hideki 分享 收藏 分享 收藏 Clinical Significance of Coiled-Coil Domain-Containing Protein 25 Expression in Esophageal Squamous Cell CarcinomaSuzuki, Takafumi; Tsujimoto, Hironori; Watanabe, Takanori; Ishibashi, Yusuke; Fujishima, Seiichiro; Itazaki, Yujiro; Kariya, Risa; Uehata, Naoyuki; Shinada, Hanae; Mochizuki, Satsuki; Kishi, Yoji; Sato, Kimiya; Ueno, Hideki 分享 收藏 Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trialShiozawa, Manabu; Sunakawa, Yu; Watanabe, Takanori; Ota, Hirofumi; Yasui, Hisateru; Yabuno, Taichi; Tei, Mitsuyoshi; Kochi, Mitsugu; Manaka, Dai; Ohori, Hisatsugu; Yamaguchi, Tatsuro; Sagawa, Tamotsu; Kotaka, Masahito; Kubota, Yutaro; Sekikawa, Takashi; Nakamura, Masato; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi; Tsuji, Akihito 分享 收藏 Development and Validation Study of the Prognostic Impact of Deep Learning-Determined Myxoid Stroma After Neoadjuvant Chemotherapy in Patients with Esophageal Squamous Cell CarcinomaKouzu, Keita; Tsujimoto, Hironori; Imamura, Yu; Kajiwara, Yoshiki; Nearchou, Ines P.; Einama, Takahiro; Takamatsu, Manabu; Haraguchi, Ikumi; Watanabe, Takanori; Horiguchi, Hiroyuki; Kishi, Yoji; Tsuda, Hitoshi; Watanabe, Masayuki; Ueno, Hideki 分享 收藏 RAS status in ctDNA and efficacy of FOLFIRI plus ramucirumab in 2nd-line therapy for RAS wild-type mCRC: JACCRO CC-16ARSunakawa, Yu; Yasui, Hisateru; Matsuura, Masato; Mine, Takashi; Yuasa, Yasuhiro; Watanabe, Takanori; Kinjo, Tatsuya; Okita, Yoshihiro; Okuyama, Hiroyuki; Yuki, Satoshi; Miyakawa, Koki; Kobara, Ayana; Ichikawa, Wataru; Fujii, Masashi; Tsuji, Akihito 分享 收藏 An update analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibodyManaka, Dai; Tsuji, Akihito; Shibutani, Masatsune; Ishibashi, Keiichiro; Yabuno, Taichi; Okamura, Shu; Furuya, Takumi; Tanaka, Chihiro; Nakamura, Masato; Sagawa, Tamotsu; Watanabe, Takanori; Shiozawa, Manabu; Sunakawa, Yu; Ota, Hirofumi; Kotaka, Masahito; Okuyama, Hiroyuki; Okita, Yoshihiro; Ichikawa, Wataru; Fujii, Masashi 分享 收藏 Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16Yasui, H.; Okita, Y.; Nakamura, M.; Sagawa, T.; Watanabe, T.; Kataoka, K.; Manaka, D.; Shiraishi, K.; Akazawa, N.; Okuno, T.; Shimura, T.; Shiozawa, M.; Sunakawa, Y.; Ota, H.; Kotaka, M.; Okuyama, H.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Tsuji, A. 分享 收藏 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCROSunakawa, Y.; Shiozawa, M.; Watanabe, T.; Ota, H.; Yasui, H.; Kochi, M.; Manaka, D.; Ohori, H.; Yamaguchi, T.; Kyogoku, T.; Sagawa, T.; Kubota, Y.; Masuishi, T.; Kotaka, M.; Sekikawa, T.; Shimada, K.; Nakamura, M.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Tsuji, A. 分享 收藏 分享 收藏 Increased Lung Uric Acid Deteriorates Pulmonary Arterial HypertensionWatanabe, Takanori; Ishikawa, Mariko; Abe, Kohtaro; Ishikawa, Tomohito; Imakiire, Satomi; Masaki, Kohei; Hosokawa, Kazuya; Fukuuchi, Tomoko; Kaneko, Kiyoko; Ohtsubo, Toshio; Hirano, Mayumi; Hirano, Katsuya; Tsutsui, Hiroyuki 分享 收藏 分享 收藏 Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancerMukai, Hirofumi; Uemura, Yukari; Akabane, Hiromitsu; Watanabe, Takanori; Park, Youngjin; Takahashi, Masato; Sagara, Yoshiaki; Nishimura, Reiki; Takashima, Tsutomu; Fujisawa, Tomomi; Hozumi, Yasuo; Kawahara, Takuya 分享 收藏 分享 收藏 Final results of hepatectomy followed by adjuvant chemotherapy with 3-month capecitabine plus oxaliplatin for colorectal cancer liver metastases: A multicenter phase 2 studyHashida, H.; Satake, H.; Tanioka, H.; Miyake, Y.; Yoshioka, S.; Watanabe, T.; Matsuura, M.; Kyogoku, T.; Inukai, M.; Kotake, T.; Okita, Y.; Matsumoto, T.; Yasui, H.; Kotaka, M.; Kato, T.; Kaihara, S.; Tsuji, A. 分享 收藏 Efficacy and safety of nivolumab for advanced gastric cancer patients with poor performance statusesMatsumoto, Toshihiko; Yamamoto, Yosuke; Kuriona, Yusuke; Okazaki, Ukyo; Kimura, Shogo; Miura, Kou; Tsuduki, Takao; Watanabe, Takanori; Mastumoto, Yusuke; Takatani, Masahiro 分享 收藏 Factors affecting enrolment in randomised controlled trials of Japanese patients with metastatic breast cancerHozumi, Yasuo; Ohsumi, Shozo; Mukai, Hirofumi; Takahashi, Masato; Akabane, Hiromitsu; Park, Youngjin; Tokunaga, Eriko; Takashima, Tsutomu; Watanabe, Takanori; Sagara, Yoshiaki; Kaneko, Tetsuji; Ohashi, Yasuo 分享 收藏 分享 收藏 Nivolumab for poor performance status patients : retrospective analysisMatsumoto, Toshihiko; Kimura, Shogo; Himei, Hitomi; Okazaki, Ukyo; Kurioka, Yusuke; Tsuduki, Takao; Takagi, Shijiro; Takatani, Masahiro; Watanabe, Takanori; Morishita, Hirofumi 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
